1. Home
  2. ENTX

ENTX

Entera Bio Ltd.

Logo Entera Bio Ltd.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-23-2024 1:31pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Founded: 2010 Country:
Israel
Israel
Employees: N/A City: JERUSALEM
Market Cap: 70.6M IPO Year: 2018
Target Price: $10.00 AVG Volume (30 days): 225.1K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.31 EPS Growth: N/A
52 Week Low/High: $0.52 - $3.35 Next Earning Date: 05-03-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks:

Stock Insider Trading Activity of Entera Bio Ltd. (ENTX)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Toledano Miranda Jayne ENTX Chief Executive Officer Dec 22 '23 Buy $0.71 23,952 $17,005.92 110,752 SEC Form 4